Ascendis Pharma announces new pooled analysis on TransCon PTH

Ascendis Pharma (ASND) announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroidism treated with TransCon PTH through Year 3 of the Company’s Phase 2 PaTH Forward and Phase 3 PaTHway trials. The data, which confirm results for each individual trial presented at major endocrinology meetings earlier this year, were shared during Kidney Week 2025 in a poster presented by lead author Dr. Elvira Gosmanova, a nephrologist at Albany Medical College and Albany VAMC. At Year 3, greater than or equal to91% of patients receiving palopegteriparatide in both trials were independent from conventional therapy and greater than or equal to84% patients had normocalcemia. Sustained and clinically meaningful improvements in eGFR were observed in 70.3%, with numerically greater improvements observed in those with lower baseline eGFR. The greatest increases in eGFR were observed in the first 6 months of treatment with TransCon PTH, with a continued upward trend thereafter. Mean eGFR increased from baseline to Year 3 by 9.8 mL/min/1.73 m2 in PaTH Forward and by 8.8 mL/min/1.73 m2 in PaTHway.